3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma
6
Neoplasms, Plasma Cell
4
Lymphoma, Non-Hodgkin
4
Leukemia
4
Infections
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Waldenstrom Macroglobulinemia
2
Sezary Syndrome
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neutropenia
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Intraocular Lymphoma
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Burkitt Lymphoma
2
Thrombocythemia, Essential
1
Recurrence
1
Primary Myelofibrosis
1
Precancerous Conditions
1
Polycythemia Vera
1
Interventions
Lenalidomide
2
ofatumumab
1
gamma-Globulins
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Saline Solution
1
SARS-CoV-2 inactivated vaccines
1
Panzyga
1
Influenza Vaccines
1
Immunoglobulins
1
Clavulanic Acid
1
Ciprofloxacin
1
Amoxicillin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Agammaglobulinemia
×
Ciprofloxacin
×
Lymphoid
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled